Wang, M. L. Et Al. 2022. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.. The New England journal of medicine , vol.386 , 2482-2494.

Wang, M. L., Jurczak, W., Jerkeman, M., Trotman, J., Zinzani, P. L., Belada, D., ... Boccomini, C.(2022). Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.. The New England journal of medicine , vol.386, 2482-2494.

Wang, Michael Et Al. "Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.," The New England journal of medicine , vol.386, 2482-2494, 2022

Wang, Michael L. Et Al. "Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.." The New England journal of medicine , vol.386, pp.2482-2494, 2022

Wang, M. L. Et Al. (2022) . "Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.." The New England journal of medicine , vol.386, pp.2482-2494.

@article{article, author={Michael L Wang Et Al. }, title={Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.}, journal={The New England journal of medicine}, year=2022, pages={2482-2494} }